Genexine Expands COVID-19 Vaccine Phase 1 Clinical Trial to Elderly Population
[Asia Economy Reporter Park Sun-mi] Genexine is expanding clinical trials of its COVID-19 vaccine candidate 'GX-19N' to include elderly groups aged 55 to 85.
According to industry sources on the 1st, the Ministry of Food and Drug Safety has approved Genexine's phase 1 clinical trial plan for GX-19N targeting individuals aged 55 to 85.
Last month, Genexine received approval for phase 1/2a clinical trials of GX-19N for adults aged 19 to 55, and separately, it is expanding phase 1 clinical trials to include the elderly group.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- While Everyone Focused on Samsung and Nix, This Company Soared 50%... Hit Record Highs for 4 Days [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
The clinical trials will be conducted at Severance Hospital and Gangnam Severance Hospital to evaluate safety and immunogenicity.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
